Brief: Lipocine Says FDA Clears LPCN 2101 IND For Adult Epilepsy Treatment
11/07/2022 13:14
July 11 (Reuters) - Lipocine Inc LPCN.O :
* LIPOCINE INC - FDA CLEARS LPCN 2101 IND FOR ADULT EPILEPSY
TREATMENT
* LIPOCINE INC - PHASE 2 PHOTOSENSITIVE EPILEPSY STUDY
PLANNED FOR
2H 2022
* LIPOCINE INC - FDA ACCEPTED COMPANY'S IND FOR ITS
NEUROACTIVE
STEROID ("NAS") CANDIDATE, LPCN 2101 AS A POTENTIAL TREATMENT
FOR ADULTS WITH EPILEPSY
Source text for Eikon: ID:nPn15xWfda
Further company coverage: LPCN.O
((reuters.briefs@thomsonreuters.com;))
Recent news on Lipocine
See all newsUS STOCKS ON THE MOVE-Halozyme, Moderna, Merck
U.S. STOCKS ON THE MOVE-Halozyme, BKV, AppFolio
U.S. STOCKS ON THE MOVE-Hecla Mining, XPO, Lipocine
Lipocine surges after Canada approves co's testosterone replacement therapy
Brief: Lipocine Announces Health Canada Approval Of Tlando For Testosterone Replacement Therapy